Recent Updates
Recently added Catalysts
REGN

REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT

Thursday, July 25, 2002 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism

Full Press Release Details

REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT.

Biotech snapshot

Cash runway
$17823M liquidity · $0M/mo burn
Low dilution risk
Lead asset
REGN7508Phase 3
Venous Thromboembolism →

Catalyst track record

+42%
best trade around REGN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for REGN.

See every catalyst's timing & PoA →